The present data indicate that DPSC administration might be effective in patients with COVID-19-induced hyper-inflammation, due to the inhibition in the production of several cytokines by activated T lymphocytes, namely, IFNγ, TNFα, IL-2, IL-9, IL-10, IL-17A, IL-18, IL-21, and IL-27. This evidence concerns the gene IL9 and COVID-19.